mk 767 has been researched along with ml-3000 in 2 studies
| Studies (mk 767) | Trials (mk 767) | Recent Studies (post-2010) (mk 767) | Studies (ml-3000) | Trials (ml-3000) | Recent Studies (post-2010) (ml-3000) |
|---|---|---|---|---|---|
| 32 | 0 | 10 | 130 | 9 | 56 |
| Protein | Taxonomy | mk 767 (IC50) | ml-3000 (IC50) |
|---|---|---|---|
| Prostaglandin E synthase | Homo sapiens (human) | 6.14 | |
| Prostaglandin G/H synthase 1 | Bos taurus (cattle) | 0.1925 | |
| Prostaglandin G/H synthase 2 | Bos taurus (cattle) | 0.21 | |
| Prostaglandin G/H synthase 1 | Ovis aries (sheep) | 0.185 | |
| Polyunsaturated fatty acid 5-lipoxygenase | Homo sapiens (human) | 0.3017 | |
| Polyunsaturated fatty acid 5-lipoxygenase | Rattus norvegicus (Norway rat) | 3.6 | |
| Prostaglandin G/H synthase 1 | Homo sapiens (human) | 2.7425 | |
| Prostaglandin G/H synthase 2 | Homo sapiens (human) | 0.422 | |
| 5-lipoxygenase | Bos taurus (cattle) | 0.47 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Morphy, R; Rankovic, Z | 1 |
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
1 review(s) available for mk 767 and ml-3000
| Article | Year |
|---|---|
Designed multiple ligands. An emerging drug discovery paradigm.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Anti-Allergic Agents; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents; Antihypertensive Agents; Antipsychotic Agents; Chemistry, Pharmaceutical; Dopamine D2 Receptor Antagonists; Drug Design; Humans; Ligands; Metabolic Diseases; Peroxisome Proliferator-Activated Receptors; Receptors, Histamine H1; Selective Serotonin Reuptake Inhibitors | 2005 |
1 other study(ies) available for mk 767 and ml-3000
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |